Organon & Co
OGN
Company Profile
Business description
Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women’s health, Biosimilars, and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
Contact
30 Hudson Street
Floor 33
Jersey CityNJ07302
USAT: +1 551 430-6900
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
10,000
Stocks News & Analysis
stocks
Ask the analyst: Can this big Covid loser scale its former heights?
Corporate Travel Management saw its profits fall through the floor during the pandemic. Our analyst Brian Han answers a reader question on what might be next.
stocks
The fight for Insignia continues
Numerous acquisition proposals vindicate Insignia's improved earnings momentum.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,660.40 | 31.30 | 0.36% |
| CAC 40 | 7,927.62 | 35.01 | 0.44% |
| DAX 40 | 21,394.93 | 16.60 | -0.08% |
| Dow JONES (US) | 44,424.25 | 140.82 | -0.32% |
| FTSE 100 | 8,502.35 | 62.85 | -0.73% |
| HKSE | 20,066.19 | 365.63 | 1.86% |
| NASDAQ | 19,954.30 | 99.38 | -0.50% |
| Nikkei 225 | 39,931.98 | 26.89 | -0.07% |
| NZX 50 Index | 13,024.70 | 35.38 | -0.27% |
| S&P 500 | 6,101.24 | 17.47 | -0.29% |
| S&P/ASX 200 | 8,408.90 | 30.20 | 0.36% |
| SSE Composite Index | 3,252.63 | 22.46 | 0.70% |